MC2313A1 - Inhibiteurs d'enzymes - Google Patents

Inhibiteurs d'enzymes

Info

Publication number
MC2313A1
MC2313A1 MC912313D MC2313D MC2313A1 MC 2313 A1 MC2313 A1 MC 2313A1 MC 912313 D MC912313 D MC 912313D MC 2313 D MC2313 D MC 2313D MC 2313 A1 MC2313 A1 MC 2313A1
Authority
MC
Monaco
Prior art keywords
enzyme inhibitors
inhibitors
enzyme
Prior art date
Application number
MC912313D
Other languages
English (en)
Inventor
Michael Szelke
David Michael Evans
David Jones
Original Assignee
Ferring Peptide Research Partn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Peptide Research Partn filed Critical Ferring Peptide Research Partn
Publication of MC2313A1 publication Critical patent/MC2313A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0227—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the (partial) peptide sequence -Phe-His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n = 2 - 6; for n > 6 see C07K5/06 - C07K5/10

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MC912313D 1990-09-07 1991-09-02 Inhibiteurs d'enzymes MC2313A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909019558A GB9019558D0 (en) 1990-09-07 1990-09-07 Enzyme inhibitors

Publications (1)

Publication Number Publication Date
MC2313A1 true MC2313A1 (fr) 1993-09-27

Family

ID=10681831

Family Applications (1)

Application Number Title Priority Date Filing Date
MC912313D MC2313A1 (fr) 1990-09-07 1991-09-02 Inhibiteurs d'enzymes

Country Status (13)

Country Link
EP (1) EP0652893A1 (fr)
JP (1) JPH06501461A (fr)
AU (1) AU8438791A (fr)
CA (1) CA2090858A1 (fr)
FI (1) FI930946A7 (fr)
GB (1) GB9019558D0 (fr)
HU (1) HUT64084A (fr)
IE (1) IE913120A1 (fr)
MC (1) MC2313A1 (fr)
NO (1) NO930731L (fr)
PT (1) PT98885A (fr)
WO (1) WO1992004371A1 (fr)
ZA (1) ZA917096B (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103612D0 (sv) * 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
US5374623A (en) * 1992-08-20 1994-12-20 Prototek, Inc. Cysteine protease inhibitors effective for in vivo use
US5783563A (en) * 1993-06-03 1998-07-21 Astra Aktiebolag Method for treatment or prophylaxis of venous thrombosis
US6984627B1 (en) 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE9301911D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
GB9318637D0 (en) * 1993-09-08 1993-10-27 Ferring Res Ltd Enzyme inhibitors
US5486623A (en) 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
US6025472A (en) * 1994-12-21 2000-02-15 Corvas International, Inc. N-substituted glycine derivatives as enzyme inhibitors
US5696231A (en) * 1994-12-21 1997-12-09 Corvas International, Inc. N-substituted glycine derivatives as enzyme inhibitors
CZ132798A3 (cs) * 1995-10-30 1999-02-17 Smithkline Beecham Corporation Inhibitory proteázy
US6586466B2 (en) 1995-10-30 2003-07-01 Smithkline Beecham Corporation Carbohydrazide-protease inhibitors
TW541316B (en) 1995-12-21 2003-07-11 Astrazeneca Ab Prodrugs of thrombin inhibitors
US6417161B1 (en) 1998-04-24 2002-07-09 3-Dimensional Pharmaceuticals, Inc. Amino acid amidinohydrazones, alkoxyguanidines and aminoguanidines as protease inhibitors
YU42401A (sh) 1998-12-14 2003-12-31 Ortho-Mcneil Pharmaceuticals Inc. Supstituisani heterociklični acil-tripeptidi korisni kao modulatori receptora trombina
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
WO2000048623A1 (fr) 1999-02-18 2000-08-24 Kaken Pharmaceutical Co., Ltd. Nouveaux derives amide secretagogues de l'hormone de croissance
EP1229914A4 (fr) 1999-11-10 2004-06-23 Smithkline Beecham Corp Inhibiteurs de protease
US6583137B1 (en) 1999-11-10 2003-06-24 Smithkline Beecham Corporation Protease inhibitors
US6596715B1 (en) 1999-11-10 2003-07-22 Smithkline Beecham Corporation Protease inhibitors
AU4344101A (en) 2000-03-21 2001-10-03 Smithkline Beecham Corp Protease inhibitors
GB0205527D0 (en) * 2002-03-08 2002-04-24 Ferring Bv Inhibitors
EP1575991A4 (fr) 2002-07-03 2008-03-19 Bio Science International Inc Peptides comprenant des aminoacides d aromatiques et leurs methodes d'utilisation
FR2846969A1 (fr) * 2002-11-08 2004-05-14 Salles Jean Pierre Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical
WO2005095327A1 (fr) * 2004-03-31 2005-10-13 Ajinomoto Co., Inc. Dérivés d'aniline
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
IL239682B (en) 2013-01-08 2018-10-31 Kalvista Pharmaceuticals Ltd History of benzylamine and 2-(aminomethyl)pyridine
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
BR112015028879B1 (pt) 2013-05-23 2022-12-20 Kalvista Pharmaceuticals Limited Compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
CA2920815C (fr) 2013-08-14 2021-09-21 Kalvista Pharmaceuticals Limited Inhibiteurs de la kallicreine plasmatique
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
ES2819218T3 (es) 2014-10-06 2021-04-15 Cortexyme Inc Inhibidores de lisina gingipaína
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
WO2017083433A1 (fr) 2015-11-09 2017-05-18 Cortexyme, Inc. Inhibiteurs d'arginine gingipaïne
WO2017207983A1 (fr) 2016-05-31 2017-12-07 Kalvista Pharmaceuticals Limited Dérivés de pyrazole en tant qu'inhibiteurs de la kallicréine plasmatique
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
KR102780603B1 (ko) 2016-09-16 2025-03-12 라이트하우스 파마슈티컬스, 인코포레이티드 리신 진지파인의 케톤 억제제
CN107043338B (zh) * 2017-03-24 2018-09-25 东华大学 一类5-氨基酮戊酸衍生物及其制备方法和应用
CN107011217B (zh) * 2017-03-24 2018-08-14 东华大学 一类脂溶性5-氨基酮戊酸衍生物及其制备方法和应用
JP7078722B2 (ja) 2017-11-29 2022-05-31 カルビスタ・ファーマシューティカルズ・リミテッド 血漿カリクレイン阻害剤を含む剤形
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
GB201910125D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
WO2021028645A1 (fr) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Inhibiteurs de la kallicréine plasmatique
GB201918994D0 (en) 2019-12-20 2020-02-05 Kalvista Pharmaceuticals Ltd Treatments of diabetic macular edema and impaired visual acuity
GB2591730A (en) 2019-12-09 2021-08-11 Kalvista Pharmaceuticals Ltd New polymorphs
WO2022079446A1 (fr) 2020-10-15 2022-04-21 Kalvista Pharmaceuticals Limited Traitements de l'œdème de quincke
EP4232031A1 (fr) 2020-10-23 2023-08-30 Kalvista Pharmaceuticals Limited Traitements de l'oedème de quincke
US20240122909A1 (en) 2021-02-09 2024-04-18 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023002219A1 (fr) 2021-07-23 2023-01-26 Kalvista Pharmaceuticals Limited Traitements de l'angio-oedème héréditaire
CA3255900A1 (fr) 2022-04-27 2023-11-02 Kalvista Pharmaceuticals Limited Formulations d'un inhibiteur de la kallicréine plasmatique
EP4673437A1 (fr) 2023-02-27 2026-01-07 Kalvista Pharmaceuticals Limited Nouvelle forme solide d'un inhibiteur de la kallicréine plasmatique
WO2025172692A1 (fr) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Sebetralstat à administrer par voie orale pour le traitement d'une attaque d'angioedème héréditaire
WO2025172693A1 (fr) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Sebetralstat oral pour le traitement d'un épisode d'angio-œdème héréditaire

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55500520A (fr) * 1978-07-18 1980-08-14
US4563305A (en) * 1981-01-07 1986-01-07 University Of Miami Radiolabelled substrates for assaying mammalian enzymes
US4835253A (en) * 1987-04-03 1989-05-30 The University Hospital Specific inhibitors of tissue kallikrein
ZA897515B (en) * 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors

Also Published As

Publication number Publication date
HUT64084A (en) 1993-11-29
EP0652893A1 (fr) 1995-05-17
AU8438791A (en) 1992-03-30
NO930731D0 (no) 1993-02-26
HU9300610D0 (en) 1993-05-28
JPH06501461A (ja) 1994-02-17
GB9019558D0 (en) 1990-10-24
IE913120A1 (en) 1992-03-11
PT98885A (pt) 1992-08-31
CA2090858A1 (fr) 1992-03-08
NO930731L (no) 1993-05-07
FI930946A0 (fi) 1993-03-03
FI930946A7 (fi) 1993-04-26
ZA917096B (en) 1992-04-29
WO1992004371A1 (fr) 1992-03-19

Similar Documents

Publication Publication Date Title
ZA917096B (en) Enzyme inhibitors
NO962269D0 (no) Enzyminhibitorer
FI965019A7 (fi) Entsyymi-inhibiittoreita
DK46793D0 (da) Enzym
DK48693D0 (da) Enzym
FI932521A0 (fi) Nytt endoglukanasenzym
FI934812L (fi) Stabiliserade entzymer
FI961622A7 (fi) Arabinoksylaania hajottavat entsyymit
DK48893D0 (da) Enzym
DK154492D0 (da) Enzym
DE69224225D1 (de) Modifiziertes Enzym
DK87592D0 (da) Enzym
DK39593D0 (da) Enzym
FI962047L (fi) Endoteliiniä muuntava entsyymi
GB9007750D0 (en) Enzyme inhibitors
DK54190D0 (da) Enzymer
DK219790D0 (da) Enzymvarianter
FI911529A7 (fi) Halogeenietyylisubstituoituja steroidientsyymiinhibiittoreita
DK122292D0 (da) Enzym
DK122492D0 (da) Enzym
DK122392D0 (da) Enzym
DK154592D0 (da) Enzym
DK122592D0 (da) Enzym
DK122192D0 (da) Enzym
IE901320L (en) Inhibitors of enzymes of collagenase family.